New approaches in medical genomics: A step forward in Parkinson's disease

December 20, 2017, Center for Genomic Regulation

It is widely known that genomics has already begun to influence medicine and that bioinformatics holds the key for developing new medical approaches, but how does medical genomics really work? Researchers at the Centre for Genomic Regulation (CRG) in Barcelona, in collaboration with scientists at the Barcelona Supercomputing Centre (BSC) and the Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), have provided a clear example of how genomics is changing medicine.

The team, led by ICREA research professor Gian Gaetano Tartaglia at the CRG, is using genomics to advance our understanding of Parkinson's disease. As published this week in Nucleic Acids Research, they have discovered a mechanism that regulates the expression of alpha-synuclein, a protein linked to Parkinson's disease and (MSA).

Parkinson's disease is the second most common human neurodegenerative disorder after Alzheimer's disease. It is a multifactorial disorder in which genetic susceptibility, aging and environmental factors converge to cause neurodegeneration. The pathological hallmark of this disease is the accumulation of alpha-synuclein, which in turn leads to cell death, and consequently, to problems in neurotransmission.

In an attempt to understand how this protein is produced, these researchers first predicted interactions between the alpha-synuclein gene and other factors found within neurons. "We used the catRAPID algorithm developed in our lab to predict which proteins interact with the RNA product of this gene. Although our method revealed several candidates, we decided to test the ones that are more relevant for Parkinson's disease and multiple system atrophy," explains Gian Gaetano Tartaglia. "Computational predictions are already key in biomedical research, allowing us to better target our bench experiments and to be faster and more innovative when searching for solutions to medical questions," he says.

Thanks to these predictions, the scientists at the CRG, together with the team of Fina Martí at IDIBAPS, were able to screen and validate the candidates in vitro (via cell culture), in vivo (with mice), and ex vivo, using human brain samples from dead patients. In this way, factors were deemed relevant or not for the development of Parkinson's disease and MSA. "We found two factors—TIAR and ELAVL1—that are crucial in neurodegeneration. Identifying these factors is relevant for further understanding Parkinson's disease and multiple system atrophy," adds Elias Bechara, CRG researcher and one of the authors of the article. "Further research is needed, but thanks to our contribution, we have now identified two new biomarker candidates. For example, these factors might be useful for early detection of the diseases through a simple blood analysis, or even serve as new targets for possible treatment," says the researcher.

The research is particularly relevant for patients with multiple system atrophy (MSA). MSA is a rare and aggressive neurodegenerative disorder, and many patients with this disorder do not respond to the dopamine medication used to treat Parkinson's disease. Moreover, MSA is even more difficult to diagnose.

The new study shows that one of the factors (TIAR) especially binds the alpha-synuclein protein in MSA patients. "It is always rewarding to find something that might be helpful for a particular , but in this case, it is even more relevant since it could also be a good biomarker to facilitate MSA diagnosis," say the researchers.

Explore further: Drug discovery: Alzheimer's and Parkinson's spurred by same enzyme

More information: Domenica Marchese et al, Discovering the 3′ UTR-mediated regulation of alpha-synuclein, Nucleic Acids Research (2017). DOI: 10.1093/nar/gkx1048

Related Stories

Drug discovery: Alzheimer's and Parkinson's spurred by same enzyme

July 3, 2017
Alzheimer's disease and Parkinson's disease are not the same. They affect different regions of the brain and have distinct genetic and environmental risk factors.

Tug of war between Parkinson's protein and growth factor

September 18, 2017
Alpha-synuclein, a sticky and sometimes toxic protein involved in Parkinson's disease (PD), blocks signals from an important brain growth factor, Emory researchers have discovered.

A new insight into Parkinson's disease protein

July 28, 2017
Abnormal clumps of certain proteins in the brain are a prominent feature of Parkinson's and other neurodegenerative diseases, but the role those same proteins might play in the normal brain has been unknown.

Parkinson's is partly an autoimmune disease, study finds

June 21, 2017
Researchers have found the first direct evidence that autoimmunity—in which the immune system attacks the body's own tissues—plays a role in Parkinson's disease, the neurodegenerative movement disorder. The findings raise ...

Single protein causes Parkinson's disease and multiple system atrophy

June 10, 2015
Several neurodegenerative disorders are caused by aggregates of a single protein known as alpha-synuclein. In collaboration with CNRS and the University of Antwerp, KU Leuven neurobiologists have discovered that the shape ...

CRISPR tech leads to new screening tool for Parkinson's disease

June 5, 2017
A team of researchers at the University of Central Florida is using breakthrough gene-editing technology to develop a new screening tool for Parkinson's disease, a debilitating degenerative disorder of the nervous system. ...

Recommended for you

Two compounds in coffee may team up to fight Parkinson's

December 10, 2018
Rutgers scientists have found a compound in coffee that may team up with caffeine to fight Parkinson's disease and Lewy body dementia—two progressive and currently incurable diseases associated with brain degeneration.

New Parkinson's disease drug target revealed through study of fatty acids

December 4, 2018
The human brain is rich in lipids. Investigators studying Parkinson's disease (PD) have become increasingly interested in lipids since both molecular and genetic studies have pointed to the disruption of the balance of the ...

A toxin that travels from stomach to brain may trigger Parkinsonism

December 4, 2018
Combining low doses of a toxic herbicide with sugar-binding proteins called lectins may trigger Parkinsonism—symptoms typical of Parkinson's disease like body tremors and slowing of body motions—after the toxin travels ...

Experimental cancer drug shows promise for Parkinson's

December 3, 2018
The study, funded by Parkinson's UK, suggests that the drug, tasquinimod, which is not yet on the market, works by controlling genes that may cause Parkinson's. This happens when the drug interacts with a protein inside brain ...

Parkinson's therapy creates new brain circuits for motor function, study finds

November 28, 2018
Scientists have uncovered that an emerging gene therapy for Parkinson's disease creates new circuits in the brain associated with improved motor movement. These findings, published today in Science Translational Medicine ...

The puzzle of a mutated gene lurking behind many Parkinson's cases

November 15, 2018
Genetic mutations affecting a single gene play an outsized role in Parkinson's disease. The mutations are generally responsible for the mass die-off of a set of dopamine-secreting, or dopaminergic, nerve cells in the brain ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.